AKBA — Akebia Therapeutics, Inc. Stock Price, Chart & AI Report

Neutral Feb 19, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics announced it will release its Q4 and full year 2025 financial results on February 26, 2026, followed by a conference call at 8:00 a.m. EST to discuss financial results and recent business highlights.

AKBA financial results Q4 2025 conference call biopharmaceutical kidney disease

Sentiment note

The article is a routine announcement of earnings release and conference call scheduling. There is no indication of positive or negative business developments, financial performance, or strategic changes. It is a standard procedural disclosure.

Positive Feb 4, 2026 • 13:00 UTC GlobeNewswire Inc. • Not Specified

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Akebia Therapeutics announced that its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company, focused on kidney disease treatments, will discuss its pipeline outlook including Vafseo prescribing expansion and Praliciguat Phase 2 clinical trial progress.

AKBA biopharmaceutical kidney disease Vafseo Praliciguat Phase 2 clinical trial pipeline investor conference

Sentiment note

The company is expanding patient access to Vafseo (approximately 275,000 patients) and advancing its pipeline with a Phase 2 clinical trial for Praliciguat, indicating progress in drug development and market penetration. The participation in a major biotech investor conference also suggests confidence in the company's direction.

Neutral Dec 1, 2025 • 14:43 UTC Benzinga • Vandana Singh

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.

QTTB AKBA biotech drug development acquisition complement inhibitor milestone payments

Sentiment note

Acquired a new drug candidate with potential future development opportunities

Positive Nov 6, 2025 • 23:30 UTC GlobeNewswire Inc. • Akebia Therapeutics

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.

AKBA vadadustat dialysis chronic kidney disease anemia clinical trial

Sentiment note

Presented favorable clinical trial data showing statistically significant benefits of their drug vadadustat in treating anemia in dialysis patients, potentially improving treatment standards

Neutral Jul 8, 2025 • 12:00 UTC GlobeNewswire Inc. • Mercedes Carrasco

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Akebia Therapeutics' Chief Commercial Officer Nik Grund will participate in a Fireside Chat at the 4th Annual Kidney Virtual Conference on July 14, 2025, discussing the company's kidney disease research and developments.

AKBA kidney disease biopharmaceutical conference webcast

Sentiment note

The article is a standard conference participation announcement without significant positive or negative indicators, presenting routine corporate communication about an upcoming industry event

Positive Jun 16, 2025 • 10:00 UTC GlobeNewswire Inc. • N/A

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

Averoa, a biopharmaceutical company, has received European marketing authorization for its oral therapy XOANACYL, which addresses iron deficiency and hyperphosphatemia in chronic kidney disease patients.

AKBA chronic kidney disease iron deficiency hyperphosphatemia oral therapy

Sentiment note

Averoa has licensed XOANACYL from Akebia Therapeutics, indicating a positive collaboration between the two companies to bring this therapy to the European market.

Positive May 28, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that it will present three posters at the European Renal Association Congress 2025.

AKBA Akebia Therapeutics kidney disease European Renal Association Congress

Sentiment note

The article highlights Akebia Therapeutics' participation in an important industry conference, which suggests the company is actively engaged in advancing its research and development efforts in the kidney disease space.

Positive Apr 2, 2025 • 09:00 UTC GlobeNewswire Inc. • N/A

AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

Averoa, a biopharmaceutical company, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its oral therapy XOANACYL, which is used to treat chronic kidney disease.

AKBA JAPAY chronic kidney disease oral therapy European Medicines Agency XOANACYL

Sentiment note

Akebia Therapeutics granted Averoa an exclusive license to develop and commercialize XOANACYL in certain regions, indicating a positive partnership between the two companies.

Positive Mar 20, 2025 • 02:17 UTC GlobeNewswire Inc. • N/A

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics, a biopharmaceutical company, announced the pricing of its $50 million public offering of 25 million shares of common stock at $2 per share. The offering is expected to close on March 21, 2025.

AKBA Akebia Therapeutics public offering common stock

Sentiment note

The company is raising $50 million through a public offering, which suggests it has confidence in its future prospects and ability to deploy the capital effectively.

Neutral Feb 7, 2025 • 10:52 UTC GlobeNewswire Inc. • Na

$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and Region - Akebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition

The global healthcare mobile robots market is expected to grow from $4.45 billion in 2024 to $10.7 billion by 2030, driven by technological advancements, shortage of skilled healthcare staff, and rising healthcare expenditures. North America is the dominant market, supported by favorable government initiatives and a developed healthcare infrastructure.

AKBA OMRNY AMZN ABBNY healthcare mobile robots market outlook technology

Sentiment note

The article mentions Akebia Therapeutics as one of the key players in the healthcare mobile robots market, but does not provide any additional information about the company's performance or outlook.

Neutral Jul 10, 2024 • 11:04 UTC GlobeNewswire Inc. • Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Initial Positive Patient - GlobeNewswire

Unicycive Therapeutics announced positive patient satisfaction results from a clinical trial of its phosphate binder drug, Oxylanthanum Carbonate (OLC). Patients preferred OLC over their prior phosphate binder therapy, and the pill burden was reduced by half.

UNCY SNY AKBA TAK Unicycive Therapeutics Oxylanthanum Carbonate Phosphate Binder Hyperphosphatemia

Sentiment note

Akebia Therapeutics' Auryxia (ferric citrate) is mentioned as one of the prior phosphate binder therapies used by patients in the trial, but the article does not provide any specific information about Akebia or its product.

Unknown May 9, 2024 • 12:10 UTC Zacks Investment Research • Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AKBA